The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Dopamine Transporter Density of the Basal Ganglia Assessed with I-123 IPT SPECT in Methamphetamine Abusers

Methamphetamine 남용자에서 I-123 IPT를 이용한 기저신경절 도파민운반체 밀도의 평가

  • Lee, Joo-Ryung (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Kewn, Do-Hun (Department of Psychiatry, National Bugok Mental Hospital) ;
  • Sung, Young-Ok (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Seo, Ji-Hyoung (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Bae, Jin-Ho (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Jeong, Shin-Young (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Lee, Sang-Woo (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Yoo, Jeong-Soo (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School) ;
  • Chi, Dae-Yoon (Department of Chemistry, Inha University) ;
  • Lee, Kyu-Bo (Department of Nuclear Medicine, Kyungpook National University Hospital, Kyungpook National University Medical School)
  • 이주령 (경북대학교 의과대학 핵의학교실) ;
  • 안병철 (경북대학교 의과대학 핵의학교실) ;
  • 권도훈 (국립부곡정신병원) ;
  • 성영옥 (경북대학교 의과대학 핵의학교실) ;
  • 서지형 (경북대학교 의과대학 핵의학교실) ;
  • 배진호 (경북대학교 의과대학 핵의학교실) ;
  • 정신영 (경북대학교 의과대학 핵의학교실) ;
  • 이상우 (경북대학교 의과대학 핵의학교실) ;
  • 유정수 (경북대학교 의과대학 핵의학교실) ;
  • 이재태 (경북대학교 의과대학 핵의학교실) ;
  • 지대윤 (인하대학교 화학과) ;
  • 이규보 (경북대학교 의과대학 핵의학교실)
  • Published : 2005.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Functional imaging of dopamine transporter (DAT) defines integrity of the dopaminergic system, and DAT is the target site of drugs of abuse such as cocaine and methamphetamine. Functional imaging the DAT may be a sensitive and selective indicator of neurotoxic change by the drug. The aim of the present study is to evaluate the clinical implications of qualitative/quantitative analyses of dopamine transporter imaging in methamphetamine abusers. Materials and Methods: Six detoxified methamphetamine abusers (abuser group) and 4 volunteers (control group) were enrolled in this study. Brain MRI was performed in all of abuser group. Abuser group underwent psychiatric and depression assessment using brief psychiatric rating scale (BPRS) and Hamilton depression rating scale (HAMD), respectively. All of the subjects underwent I-123 IPT SPECT (IPT SPECT). IPT SPECT image was analysed with visual qualitative method and quantitative method using basal ganglia dopamine transporter (DAT) specific/non-specific binding ratio (SBR). Comparison of DAT SBR between abuser and control groups was performed. We also performed correlation tests between psychiatric and depression assessment results and DAT SBR in abuser group. Results: All of abuser group showed normal MRI finding, but had residual psychiatric and depressive symptoms, and psychiatric and depressive symptom scores were exactly correlated (r=1.0, p=0.005) each other. Five of them showed abnormal finding on qualitative visual I-123 IPT SPECT Abuser group had lower basal ganglia DAT SBR than that of control ($2.38{\pm}0.20\;vs\;3.04{\pm}0.27$, p=0.000). Psychiatric and depressive symptoms were negatively well correlated with basal ganglia DAT SBR (r=-0.908, p=0.012, r=-0.924, p=0.009). Conclusion: These results suggest that dopamine transporter imaging using I-123 IPT SPECT may be used to evaluate dopaminergic system of the basal ganglia and the clinical status in methamphetamine abusers.

목적: 도파민운반체의 기능적 영상술은 도파민 신경계의 시냅스전 신경말단의 상태를 나타내 줄 수 있어, 기저신경절을 침범하는 파킨슨 병 등의 진단 및 중증도 판단에 이용될 수 있으며, 도파민운반체가 코카인이나 methamphetamine 등 의존성 약물의 목표 부위이므로 이러한 약물의 남용자의 평가에 이용될 수 있다. 본 연구는 한국에서 생산된 도파민운반체 영상용 방사성의약품을 사용한 뇌 SPECT영상을 이용하여 methamphetamine 남용자에서 나타나는 소견과 이의 임상적 의의를 알아보고자 하였다. 대상 및 방법: Methamphetamine 남용자 6명 (남용자군, 전부 남자, 평균연령: $32{\pm}6.8$) 및 정상대조군 4명(대조군, 남:여=3:1, 평균연령=$44.0{\pm}14.7$세)을 대상으로 하였다. 남용자군 6명 모두에서 뇌 MRI가 시행되었다. 남용자군에서는 정신과적 증상과 우울증 증상을 정량적으로 평가하였다. 도파민운반체 영상은 I-123 IPT 185 MBq을 정맥 주사한 후 2시간에 삼중헤드 감마카메라(Prism 3000, Picker, USA)를 이용하여 뇌 SPECT 영상을 얻었다. 정성적인 판독과 함께, 정량적 분석으로 기저신경절 부위에 관심영역을 그려 기저신경절의 방사능량을 구하였고, 배후 방사능량은 후두엽 부위에 관심영역을 그려 방사능량을 구하였다. 기저신경절과 배후 방사능량을 이용하여 기저신경절 도파민운반체 특이결합/비특이결합 비율(특이결합비) (기저신경절방사능량-배후방사능량/배후방사능량)을 구하였다. 각군의 도파민운반체 특이겹합비를 비교하였으며, 남용자군에서는 정신과적 증상(Brief Psychiatric Rating Scale: BPRS) 및 우울증 증상 정도(Hamilton Depression Rrating Scale : HAMD)와 도파민운반체 특이겹합비의 상관성을 알아보았다. 결과: 남용자군 6명 모두는 뇌 MRI상 특이 소견이 관찰되지 않았으나, 모든 환자는 정신과적 증상과 우울증 증상을 나타내었으며 BPRS 점수와 HAMD 점수는 서로 밀접한 상관성을 보여 주었다(r=1.0, p=0.005). 남용자군의 I-123 IPT 뇌 SPECT의 정성적분석에서 5명(83.3%)이 기저신경절의 전체적 섭취가 불균등하고 미측의 섭취가 감소되어 비정상으로 판독 되었으며, 1명은 정상으로 판독되었다. 남용자군은 대조군에 비하여 낮은 기저신경절 도파민운반체 특이겹합비를 나타내었다($2.38{\pm}0.20\;vs\;3.04{\pm}0.27$, p=0.000) 남용자군의 BPRS 점수와 HAMD 점수가 높을수록 낮은 기저신경절 특이겹합비를 나타내어 역의 상관관계를 보였다(r=-0.908, p=0.012, r=-0.924, p=0.009). 결론: I-123 IPT뇌 SPECT는 흑질-선조체 도파민신경계의 손상을 일으키는 중증의 methamphetamine 남용자의 평가에 이용될 수 있다고 생각된다.

Keywords

References

  1. 대검찰청 마약과. 마약류 범죄의 개황. 마약류 범죄백서. 2004;28-43
  2. O'Dea PJ, Murphy B, Balzer C. Traffic and illegal production of drugs in rural America. NIDA Res Monogr 1997;168:79-89
  3. Woolverton ML, Cervo L, Jonanson CE. Effect of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacol iochem Behav 1994;21:737-41
  4. Volkow ND, Chang L, Wang G, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psych 2001;158:377-82 https://doi.org/10.1176/appi.ajp.158.3.377
  5. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psych 2001;158:1206-14 https://doi.org/10.1176/appi.ajp.158.8.1206
  6. Sato M, Numach Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia Bull 1992;18:115-22 https://doi.org/10.1093/schbul/18.1.115
  7. Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N. Methamphetamine-associated obsessional symptoms and effective resperidone treatment: a case report. J Clin Psych 1999;60:337-8
  8. Buffenstein A, Heaster J, Ko P. Chronic psychotic illness from methamphetamine(letter). Am J Psych 1999;156:662
  9. Gibb JW, Johnson M, Elayan I, Lim HK, Matsuda L, Hanson GR. Neurotoxicity of amphetamines and their metabolites. NIDA Res Monogr 1997;173:128-45
  10. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine induced degeneration of dopamine neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 2002;22:8951-60
  11. Sandoval V, Hanson GR, Fleckenstein AE. Methamphetamine decreases mouse striatal depamine transporter activity: roles of hyperthermia and dopamine. Eur J Pharmacol 2000;409:265-71 https://doi.org/10.1016/S0014-2999(00)00871-2
  12. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998;18:8417-22
  13. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol App Pharmacol 2005;204:355-60 https://doi.org/10.1016/j.taap.2004.08.013
  14. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001;21:9414–8
  15. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-23 https://doi.org/10.1002/mds.10592
  16. Goodman MM, Kung MP, Kabalka GW, Kung HF, Switzer R. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2$\beta$-(c-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents. J Med Chem 1994;37:1535-42 https://doi.org/10.1021/jm00036a020
  17. Chi DY. Radioligand for imaging dopamine and serotonin receptors and transporters. Korean J Nucl Med 2000;34:159-68
  18. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR, et al. Mapping cocaine binding sites in humanand baboon brain in vivo. Synapse 1995;4:371-7 https://doi.org/10.1002/syn.890040412
  19. Chung KH, Lim CH, Lee DR, Jin C, Chi DY. Synthesis and binding affinities of $2{\beta}$-(3-iodoallyloxycarboxyl)-$3{\beta}$-(4-substitutedaryl) tropane analogues as ligands for the dopamine transporter studies. Bioorg Med Chem Lett 2001;11:3077-80 https://doi.org/10.1016/S0960-894X(01)00625-4
  20. Ryu WG, Kim TH, Ryu YH, Cheon KA, Yun M, Chi DY et al. Dopamine transporter density of the basal ganglia in children with attention deficit hyperactivity disorder assessed with I-123 IPT SPECT. Korean J Nucl Med 2003;37:235-44
  21. Ryu YH, Kim TH, Ryu WG, Park SY, Chi DY, Choi TH, et al. Dopamine transporter density assessed with I-123 IPT SPECT before and after risperidone treatment in children with Tourette's disorder. Korean J Nucl Med 2004;38:41-51
  22. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812 https://doi.org/10.2466/PR0.10.3.799-812
  23. Williams BW. A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psych 1987;45:742–7
  24. Volz TJ, Schenk JO. A comprehensive atlas of the topography of functional group of the dopamine transporter. Synapse 2005;58:72-94 https://doi.org/10.1002/syn.20183
  25. Mozley PD, Kim H-J, Gur RC, Tatsch K, Muenz LR, McElgin WT, Kung M-P, Mu M, Myers AM, Kung HF. I-123 IPT SPECT imaging of the CNS dopamine transporters: non-linear effects of normal aging on striatal uptake values. J Nucl Med 1996;37:1965–70
  26. Schwarz J, Tatsch K, Linke R, Pogarell O, Mozley PD, Kung HF. Measuring the decline of dopamine transporter binding in patients with Parkinson's disease using 123I-IPT and SPECT. Neurol 1997;48(Suppl):A208
  27. 대검찰청 마약과. 마약류의 개요. 마약류 범죄백서. 2004;2-27
  28. Kuczenski R, Segal DS. Neurochemistry of methamphetamine. In : Cho A, Segal DS. Amphetamine and its analogs. Eds. San Diego : Academic press; 1994. p. 81-113
  29. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of interstriatal dopamine injections. Proc Natl Acad Sci USA 1996;93:1956-1961
  30. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Reviews 2001;36:1-22 https://doi.org/10.1016/S0165-0173(01)00054-6
  31. Segal DS, Kuczenski , O'Neil ML, Melega WP, Cho AK. Prolonged exposure of rats to intravenous methamphetamine:behavioral and neurochemical characterization. Psychopharmacol 2005;180:501-12 https://doi.org/10.1007/s00213-005-2188-4
  32. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME. Recovery of striatal dopamine function after acute amphetamine and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 1997;766:113-20 https://doi.org/10.1016/S0006-8993(97)00548-9
  33. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. Methamphetamine induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 2001;21:1413-9
  34. Liua HC, Lina SK, Liud SK, Chena SL, Hue CJ, Chang JG, et al. DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. Psych Genetics 2004;14:33-7 https://doi.org/10.1097/00041444-200403000-00005
  35. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental Parkinsonsim in redents and induces striatal increase of neurotrophic factors. J Neurochem 1998;71:2439-46 https://doi.org/10.1046/j.1471-4159.1998.71062439.x
  36. Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: comparment analysis for $\beta$-CIT binding with positron emission tomography. Ann Neurol 1999;45:601-10 https://doi.org/10.1002/1531-8249(199905)45:5<601::AID-ANA8>3.0.CO;2-0
  37. Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, et al. PET imaging of serotonin type 2A receptors in latelife neuropsychiatric disorders. Am J Psych 1999;156:1871-8
  38. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, DiBella D, et al. Influence of functional polymorphism within the promotor of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psych 1999;156:1450-2